AbbVie Inc
ABBV · NYSE212.00
212.00
USD0.600.28%Дата
Тикеры
Заголовок
Источник
AbbVie closes $200M Nimble Therapeutics acquisition
SeekingAlpha
STARTS NOW! Rebel Edge 🏴☠️1pm line up: U.S. crude oil prices are dropping due to weak demand from China and expected higher U.S. production after the election. WTI is notably lower, part of a wider commodity slump. Stocks $TSLA $COIN $ABBV $HOOD Sports Detroit's kicker makes 58… https://t.co/mZXNAn84q8 https://t.co/HBCDrov0gz
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
MarketWatch
M&A deals roundup: AbbVie, Blackstone, Take-Two Interactive and more
SeekingAlpha
AbbVie to buy Aliada Therapeutics for $1.4B in cash
SeekingAlpha
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease
MarketWatch
AbbVie completes acquisition of Cerevel Therapeutics
SeekingAlpha
Cerevel Therapeutics ticks higher amid Nasdaq delisting notice for AbbVie deal
SeekingAlpha
Cerevel gains as AbbVie says it expects deal to close soon (update)
SeekingAlpha
Cerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVie
SeekingAlpha
Cerevel Therapeutics drops amid report on FTC review of AbbVie deal
SeekingAlpha
AbbVie buys bowel disease drug developer Celsius for $250M
SeekingAlpha
Cerevel Therapeutics sinks amid some worry on FTC review of AbbVie deal
SeekingAlpha
AbbVie says FDA approves Skyrizi for ulcerative colitis
MarketWatch
Cerevel Therapeutics gains after AbbVie says making good progress with FTC
SeekingAlpha
$COR $UNH $ABBV $ACAD $NVS $REGN | After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February Cencora publicly acknowledged the breach on February 27 after filing a notice with government regulators. Despite… https://t.co/8qToXmkbOW https://t.co/h8ZQs2luQB
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
CNBC
Landos shares rocket 170% on AbbVie takeover deal
SeekingAlpha
FDA grants full approval to AbbVie/ImmunoGen drug Elahere
SeekingAlpha
AbbVie plans to offer senior notes to fund Immunogen, Cerevel deals
SeekingAlpha
AbbVie taps new CEO as it faces fresh competition for blockbuster drug Humira
MarketWatch
Cerevel, AbbVie get FTC Second Requests for more merger info
SeekingAlpha
AbbVie revises Q1 earnings outlook as ImmunoGen deal closes
SeekingAlpha
AbbVie lowers first-quarter guidance after closing acquisition ImmunoGen
MarketWatch
ImmunoGen spikes as HSR waiting period for AbbVie deal expires
SeekingAlpha
AbbVie – Cerevel deal reportedly followed unusual options trading
SeekingAlpha
AbbVie – Cerevel M&A deal lifts Reviva, Karuna
SeekingAlpha
AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion - CNBC
CNBC
AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal
MarketWatch
Cerevel Therapeutics jumps after Abbvie agrees to $8.7B takeover (update)
SeekingAlpha
ImmunoGen downgraded on Wall Street expecting AbbVie deal success
SeekingAlpha
AbbVie to acquire cancer drugmaker ImmunoGen for $10B cash
SeekingAlpha
AbbVie results beat expectations despite low-cost competition to blockbuster Humira
MarketWatch
AbbVie buys Parkinson's disease drug developer Mitokinin
SeekingAlpha
AbbVie shares jump as results beat expectations despite blockbuster Humira’s declining sales
MarketWatch
Earnings Outlook: AbbVie turns to newer immunology drugs as blockbuster Humira faces lower-cost competition
MarketWatch
Abbvie, Bristol Myers competed with Merck in sale of Prometheus - report
SeekingAlpha
AbbVie on track for biggest decline in about three years as newer drug sales lag estimates
MarketWatch
Частые вопросы
Чего же вы ждёте?Начните получать прибыль уже сегодня
©
2025
Все права защищены